ISRCTN31380482 https://doi.org/10.1186/ISRCTN31380482

Partnership in prostate cancer care

Submission date 19/12/2016	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol
Registration date 09/01/2017	**Overall study status** Completed	[_] Statistical analysis plan [X] Results
Last Edited 10/09/2020	**Condition category** Cancer	[_] Individual participant data

Plain English summary of protocol
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-using-an-online-assessment-tool-for-prostate-cancer-icare-p

Contact information

Type(s)
Scientific

Contact name
Dr Veronica Nanton

Contact details
Warwick Medical School
University of Warwick
Coventry
United Kingdom
CV4 7AL

Additional identifiers

Protocol serial number
32774

Study information

Scientific Title
Partnership in Prostate Cancer Care: the feasibility of an integrated system to improve patient outcomes and experience (the ICARE-P Study)

Acronym
ICARE-P

Study objectives
The aim of this study is to assess the feasibility of carrying out a future trial to compare a new model of integrated care for prostate cancer patients with standard care.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Yorkshire and the Humber – South Yorkshire NRES, 04/08/2016, ref: 206153

Study design
Non-randomised; Interventional; Design type: Process of Care, Education or Self-Management, Complex Intervention, Management of Care

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Specialty: Primary Care, Primary sub-specialty: Cancer; UKCRC code/ Disease: Cancer/ Malignant neoplasms of urinary tract

Interventions
Intervention group: Intervention practices are recruited on the basis of their being willing to send practice nurses for Macmillan Cancer follow up training and the additional prostate specific training delivered by members of the project team.
Patients will be invited to complete the CHAT-P holistic needs assessment online either alone, with family, friends, peer supporter, or a member of the research team, as is their preference. Links are provided within CHAT-P to sources of advice and information depending on the needs identified. Following completion of the first of 3 HNAs the patient will be directed to make an appointment with the Practice Nurse to discuss any issues of concern identified and personalise the automated Care Plan. The nurse will discuss current concerns which may be physical issues arising from prostate cancer treatment, emotional or social issues, or concerns related to aspects of care. The nurse will discuss aspects of lifestyle and self-management with the patient and where relevant help patients set realistic goals. Where indicated, the nurse will advise the patient regarding further sources of support and advice on specific issues. The nurse will highlight matters of clinical concern to the secondary care team or the GP as necessary. The HNA will be recompleted at intervals specified in our study timeline. All intervention group participants will complete the HNA at least three times during the 8/9-month study period, and hence may have at least three planned follow-up appointments with the Practice Nurse.

Control group: Control practices include any practices within the same CCG who would agree to recruit men with prostate cancer to complete the outcome measures.
Participating patients will receive usual care for the duration of the study and will complete study outcome measures at baseline and at 8/9 months.

Intervention Type
Other

Phase
Phase II

Primary outcome(s)
Feasibility is assessed through recording the the percentage of eligible men recruited and the percentage of men who complete the Holistic Needs assessments at baseline, 6 and 9 months

Key secondary outcome(s))
1. Cancer survivors' supportive care needs will be assessed using the cancer survivors unmet needs survey (CASUN) at baseline, 6 and 9 months
2. Quality of life will be measured using the EORTC QLQ-C30 at baseline and 9 months
3. Quality adjusted life years will be measured using the EQ-5D-5L at baseline and 9 months
4. Mental wellbeing will be measured using the Warwick and Edinburgh Mental Well-being scale (WEMWBS) at baseline and 9 months
5. Prostate specific concerns will be measured using EPIC at baseline and 9 months
6. Participant engagement in their healthcare will be measured using the Patient Activation measure (PAM) at baseline 3 and 9 months

Completion date
30/11/2017

Eligibility

Key inclusion criteria
1. Confirmed diagnosis of prostate cancer and are at any stage of the care pathway
2. Under any treatment regime
3. Diagnosed and/or treated at University Hospitals Birmingham (UHB) or are currently undergoing treatment at UHB
4. Able to read written and comprehend spoken English and complete outcome measures
5. Judged by their GP to have the capacity to participate
6. Aged 18 years or over
7. Able and willing to give informed consent

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
Male

Key exclusion criteria

1. Aged under 18 years
2. Unable to give informed consent or complete outcome measures
3. Living in a care setting, suffering from severe mental health problems or unable to communicate in English

Date of first enrolment
02/02/2017

Date of final enrolment
28/02/2017

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Woodland Road Surgery
Woodland Road
Northfield
Birmingham
United Kingdom
B31 2HZ

Study participating centre
Maypole Health Centre
10 Sladepool Farm Road
Birmingham
United Kingdom
B14 5DJ

Study participating centre
Ash Tree Surgery
1536 Pershore Road
Stirchley
Birmingham
United Kingdom
B30 2NW

Study participating centre

Kings Norton Surgery
66 Redditch Road
Birmingham
United Kingdom
B38 8QS

Study participating centre
West Heath Medical Centre
West Heath Medical Centre
194-196 West Heath Road
Birmingham
United Kingdom
B31 3HB

Study participating centre
Riverbrook Medical Centre
3 River Brook Drive
Birmingham
United Kingdom
B30 2SH

Study participating centre
The Wand Medical Centre
15 Frank Street
Highgate
Birmingham
United Kingdom
B12 0UF

Study participating centre
Sparkbrook Community and Health Centre
34 Grantham Road
Sparkbrook
Birmingham
United Kingdom
B11 1LU

Study participating centre
St George's Surgery
119 School Road
Moseley

Birmingham
United Kingdom
B13 9TX

Study participating centre
Greet Medical Practice
50 Percy Road
Birmingham
United Kingdom
B11 3ND

Study participating centre
Fernley Medical Centre
560 Stratford Road
Birmingham
United Kingdom
B11 4AN

Study participating centre
The Balaji Surgery
2 Blackford Road
Sparkhill
Birmigham
United Kingdom
B11 3SH

Study participating centre
Bournville surgery
41B Sycamore Road
Birmingham
United Kingdom
B30 2AA

Sponsor information

Organisation
NHS Birmingham South and Central CCG

Funder(s)

Funder type
Government

Funder Name
National Institute for Health Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
The current data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary
Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	28/07/2017		Yes	No
Participant information sheet	version V1.3	23/08/2016	09/01/2017	No	Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Plain English results				No	Yes